Provided by Tiger Trade Technology Pte. Ltd.

Regenxbio

8.59
-0.1400-1.60%
Volume:345.50K
Turnover:2.98M
Market Cap:567.05M
PE:-2.28
High:8.79
Open:8.63
Low:8.47
Close:8.73
52wk High:16.19
52wk Low:5.46
Shares:66.01M
Float Shares:57.34M
Volume Ratio:0.88
T/O Rate:0.60%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.7652
EPS(LYR):-3.7593
ROE:-137.63%
ROA:-21.20%
PB:7.90
PE(LYR):-2.29

Loading ...

Regenxbio Reports First Quarter 2026 Financial Results and Operational Highlights

THOMSON REUTERS
·
May 14

Regenxbio Q1 License & Royalty Revenue USD 5.09 Million

THOMSON REUTERS
·
May 14

Regenxbio Q1 Operating Expenses USD 89.755 Million

THOMSON REUTERS
·
May 14

Regenxbio Inc - Expects Cash Position to Fund Operations Into Early 2027

THOMSON REUTERS
·
May 14

Regenxbio's muscle disorder therapy meets main goal in late-stage study

Reuters
·
May 14

Regenxbio Inc - Rgx-202 Shows Favorable Safety Profile With >80% Full Capsid Purity

THOMSON REUTERS
·
May 14

Regenxbio Inc - Plans Potential Commercial Launch of Rgx-202 in 2027

THOMSON REUTERS
·
May 14

Regenxbio Inc - Two Serious Adverse Events Reported, Both Resolved Without Sequelae

THOMSON REUTERS
·
May 14

Regenxbio Inc - Phase Iii Study Achieves Primary Endpoint With 93% of Patients Above 10% Microdystrophin Expression

THOMSON REUTERS
·
May 14

Regenxbio Announces Positive Topline Results From Pivotal Phase Iii Affinity Duchenne® Study of Rgx-202

THOMSON REUTERS
·
May 14

Regenxbio Inc - Rgx-202 Shows Significant Correlation Between Microdystrophin Expression and Functional Improvement

THOMSON REUTERS
·
May 14

NASDAQ TRADE HALT HALT NEWS PENDING AT 06:55 AM

Reuters
·
May 14

Regenxbio CMO Steve Pakola disposes of shares worth $168,704.18

Reuters
·
May 14

Regenxbio Inc expected to post a loss of $1.34 a share - Earnings Preview

Reuters
·
May 12

Regenxbio Inc expected to post a loss of $1.34 a share - Earnings Preview

Reuters
·
May 08

Regenxbio to present at ASGCT annual meeting

Reuters
·
May 07

Regenxbio Announces Presentations at the American Society of Gene & Cell Therapy 2026 Annual Meeting

THOMSON REUTERS
·
May 07

Regenxbio updates financial calendar with first-quarter results release, webcast

Reuters
·
May 06

Regenxbio announces annual shareholder meeting, releases preliminary proxy statement

Reuters
·
Apr 04

Regenxbio shares drop 17.8% due to RGX-111 securities class action; lead plaintiff deadline set for April 14, 2026

Reuters
·
Mar 26